CLOSE X

About Us

We aim to build a better every day, always thinking beyond and how we can have a positive impact.

CLOSE X

Who We Help

We help you make strategic decisions, achieve your long-term objectives, reduce costs and grow your bottom line, whilst also keeping you fully compliant with the latest tax obligations.

73 Cornhill

London, EC3V 3QQ

Corporate Finance, Deal Advisory

Industry report: Life Sciences

Industry report: Life Sciences

From 2022 to 2023, the UK Life Sciences industry experienced notable growth. Investment from the sector surged, with M&A activity reaching over £43 billion in 2023, up from £35 billion in 2022.

In our latest industry report, Corporate Finance Partner Nick Wallis, and Director Sam Barr, provide a comprehensive review of the Life Sciences landscape, spotlighting recent M&A activity, as well as the current trends and outlook for the future.

Key takeaways from the report include:

  • A notable trend in the Life Sciences industry is the rise of international collaborations, aimed at enhancing research quality and outcomes. In May 2024, Boehringer Ingelheim’s c. £1 billion partnership with Oxford-based biotech firm, Ochre Bio exemplified growing interest in collaborating with R&D-focussed enterprises.
  • A challenge to the UK’s competitive position in this sector is the decline in foreign direct investment (FDI). Inward investment into the UK in 2023 totalled £0.8 billion, reflecting a 21% decrease compared to 2022.
  • The global Life Sciences industry has seen a resurgence in major deal-making, with M&A investment reaching £191 billion in December 2023.
  • Under the new Labour government, the industry is expected to benefit from pledges to a more certain funding environment and an increasingly streamlined funding process.
OUR EXPERTS

For more information contact

LET US HELP

Contact us

73 Cornhill London EC3V 3QQ

Let’s get started

Contact page

Newsletter
(Required)

Contact Us